Skip to Content
Merck
  • Resolution of neuropsychological and FDG-PET abnormalities in a patient with neuropsychiatric systemic lupus erythematosus.

Resolution of neuropsychological and FDG-PET abnormalities in a patient with neuropsychiatric systemic lupus erythematosus.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology (2013-10-01)
Anahita Adeli, Daniel A Drubach, Mary M Machulda
ABSTRACT

Many patients with systemic lupus erythematosus have central nervous system involvement. Routine diagnostic studies may not yield evidence of neuropsychiatric dysfunction and are therefore not useful as objective measures to monitor treatment response. We present a case of a 64-year-old woman whom we diagnosed with systemic lupus erythematosus by the American College of Rheumatology criteria after she reported recent cognitive decline. Neuropsychological assessment showed prominent deficits, and an F-18 fluorodeoxyglucose positron emission tomography scan of the brain showed significant abnormalities. Both the neuropsychiatric and scan abnormalities improved dramatically with immunosuppressive treatment. F-18 fluorodeoxyglucose positron emission tomography shows promise in the diagnosis and treatment monitoring of patients who have lupus with neuropsychiatric involvement.

MATERIALS
Product Number
Brand
Product Description

Supelco
Mycophenolic acid solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Mycophenolate mofetil, ≥98% (HPLC)
SKU
Pack Size
Availability
Price
Quantity
Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Mycophenolic acid, ≥98%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Mycophenolic acid, powder, BioReagent, suitable for cell culture
SKU
Pack Size
Availability
Price
Quantity